NCT07284784Phase 2, phase 3Recruiting

A Study of Buntanetap in Participants With PD

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2029-09Estimated

Enrollment · participants500Estimated

Source updated2026-09-21Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

Posted 2026-01-08 · 1 field changed

Recruitment status changed

− Before

~~Not yet recruiting~~

+ After

Recruiting

Check registry source

Study details

Conditions studied

Parkinson's Disease (PD); Deep Brain Stimulation

Treatments or interventions studied

buntanetap/posiphenDrug

Primary outcomes · main study measures

Read the study measures

measure: Safety of buntanetap; description: Safety assessments of participants with PD receiving treatment with buntanetap; timeFrame: 36-months of treatment; measure: Adverse Events (AE); description: An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention; timeFrame: 36-months of treatment; measure: Treatment Emergent Adverse Events (TEAE); description: TEAE is an event that emerges during treatment, having been absent pretreatment, or worsens relative to the pretreatment state; timeFrame: 36-months of treatment; measure: Serious Adverse Events (SAE); description: SAE is defined as any untoward medical occurrence that results in death, is life-threatening, requires inpatient hospitalization, or prolongation of an existing hospitalization, results in persistent or significant disability or incapacity, is a birth defect or congenital anomaly; timeFrame: 36-months of treatment

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history